News

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

VCN-01 has been granted rare pediatric disease designation by the FDA for the treatment of retinoblastoma, a rare eye cancer.

Avutometinib plus defactinib shows promising early results in pancreatic cancer, earning an orphan drug designation from the FDA.

The investigational new drug application for UB-VV111, potentially the first in situ generated CD19 CAR T-cell therapy, has been cleared by the FDA, and a phase 1 trial in hematologic malignancies will begin.

The investigational mRNA therapy BNT111 plus cemiplimab showed better overall response rates compared with historical controls in patients with stage III/IV melanoma refractory to anti-PD-(L)1 therapy.

The FDA has granted expanded access to TLX101-CDx, a promising PET imaging agent for diagnosing and monitoring glioma.

Findings from the phase 3 PERSEUS study support the approval of subcutaneous daratumumab and bortezomib, lenalidomide, and dexamethasone in this patient population.

Harry Erba, MD, PhD, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia or myelodysplastic syndrome.

A phase 1 trial of COM503 in metastatic or advanced solid tumors is expected to begin in Q4 2024.

The FDA has extended the PDUFA target action date for the new drug application of revumenib for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia to December 26, 2024.

The FDA granted priority review to asciminib for the treatment of newly diagnosed, Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia.

The NCCN has updated its guidelines to recommend imetelstat as a top treatment for symptomatic anemia in lower-risk MDS, following its FDA approval based on encouraging phase 3 trial results.

Replacing fluorouracil with paclitaxel in combination with pembrolizumab and carboplatin appears to be efficacious and tolerable in patients with recurrent/metastatic head and neck cancer.

The combination of acalabrutinib and venetoclax with or without obinutuzumab improved survival vs standard chemotherapy in patients with previously untreated chronic lymphocytic leukemia.

The FDA approval of Guardant Shield marks the second blood-based diagnostic test for colorectal cancer in those age 45 and older at average risk of the disease.

The FDA cleared ADC, ZW191, for difficult-to-treat cancers, immunotherapy showed varied efficacy in angiosarcomas, and the cabozantinib/nivolumab combination demonstrated promising results in RCC. We also cover FDA setbacks for botensilimab/balstilimab in mCRC, and the lackluster effects of nivolumab/tivozanib for RCC.

A new dendritic cell vaccine has shown promising results in extending survival for pancreatic cancer patients by stimulating the immune system to fight tumor cells.

SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy.

The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.

Findings from the phase 2 NeoPembrOV study supported the addition of pembrolizumab to neoadjuvant chemotherapy before surgery in high-grade serous ovarian cancer.

The FDA’s Oncologic Drugs Advisory Committee convened to assess the need for rigorous trial designs evaluating perioperative regimens in resectable non–small cell lung cancer.

A phase 2 trial shows that THIO, a new investigational drug, combined with cemiplimab, may be an effective and well-tolerated treatment for patients with advanced non–small cell lung cancer who have exhausted other options.

Patients treated with hormone-modulating therapy for breast cancer had a reduced risk of developing Alzheimer disease or dementia compared with patients treated with other agents.

Matthew Hadfield, DO, discusses his interest in immunotherapy and the toxicities associated with them.

The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective inhibitor, in the HEROEX-1 trial.

Bhavana Pothuri, MD, discussed the importance of testing and accessing treatment for patients with endometrial cancer.

The FDA has granted a fast track designation to ozuriftamab vedotin for treating recurrent/metastatic head and neck cancer that progressed after prior therapies.

TLX007-CDx, if approved by the FDA, has the potential to become a new PSMA PET imaging agent for prostate cancer.

Laura Huppert, MD, discussed a retrospective study exploring the sequential use of antibody-drug conjugates for the treatment of HER2-low metastatic breast cancer.